301results about How to "Reduce obesity" patented technology

The invention provides compositions comprising an effective amount of an agent that inhibits a BET protein (e.g., Brd2, Brd3, Brd4), and methods of using such compositions for treating or preventing metabolic syndrome, obesity, type II diabetes, insulin resistance, and related disorders characterized by undesirable alterations in metabolism or fat accumulation.

Oil compositions containing Hoodia plant extract dissolved in medium chain tri-acyl-glycerides. Edible emulsions comprising the inventive oil compositions are also disclosed.

The present invention includes compositions and methods of making and using a dietary supplement manufactured from one or more natural polysaccharides previously incubated with a probiotic bacteria in a bioreactor system, wherein the bacteria process the polysaccharides and the resulting processed polysaccharide are provided in the nutritional supplement.

The invention discloses fruit-vegetable nutrition powder and a preparation method thereof. The fruit-vegetable nutrition powder and the preparation method thereof have the advantages that natural plants having weight losing effects are taken as raw materials, low-temperature extraction and biological enzymolysis techniques are adopted, active ingredients in the natural plants are maintained to the greatest extent, weight-losing factors good in weight losing effect, such as dietary fibers, plant extracts, tea extracts, spice extracts, Chinese herb extracts, probiotics powder, probiotics factors and bamboo charcoal powder, are compounded on the basis of existing fruit and vegetable nutrition powder scientifically, nutrient substances with weight losing effects, such as albumen powder, malt extracts and wheat malt powder, are also compounded, nutrients such as compound amino acids, vitamins and mineral substances are added, and automatic regulation, digestion and absorption level and capability of human bodies are maintained and improved in terms of satiety, stomach and intestine flora regulation, traditional Chinese medicine health care, fat absorption and removal and the like, so that intake and secondary synthetic approaches of fat of the human bodies are reduced, normal nutrient ingestion and metabolic levels of the human bodies are not affected, and a virtuous circle of health-care weight loss is achieved.

The use of probiotic bacteria capable of promoting the development of an early bifidogenic intestinal microbiota in the manufacture of a medicament or therapeutic nutritional composition for reducing the risk of development of overweight or obesity of an infant later in life.

Compounds comprising an angiopoietin-like protein 6 (Angptl6) peptide for use in the treatment of metabolic syndrome, in particular, obesity and insulin resistance are described.

A method for the treatment of obesity, diabetes, high cholesterol and related diseases including hyperglycemia, lipid disorders, hyperglyceridemia, dyslipidemia and atherosclerosis in mammals using anthocyanins, anthocyanidins, ursolic acid and/or betulinic acid is described. Compositions adapted for these treatments are also described.

Disclosed is a antihypelipidemic and antihyperglycemic health food for preventing diseases including cardiovascular disease, diabetes, adjusting internal secretion, resisting osteoporosis and cancer, and beauty treatment. The raw materials include soybean powder 15-30 parts, pumpkin powder 15-30 parts, soybean isoflavones 0.5-1.5 parts, soybean saponin 2-5 parts, astragalus root 10-20 parts, wolfberry fruit 10-15 parts, kudzuvine root 10-15 parts, Chinese yam 10-15 parts, lotus plumule 6-10 parts, Siberian solomonseal rhizome 6-10 parts, cassia seed 6-10 parts, lily 5-8 parts, mulberry leaf 5-8 parts and ginseng 3-5 parts.

A Chinese medicine in the form of capsule for treating hyperlipemia and fatty liver and lossing weight is prepared from 16 Chinese-medicinal materials including tetrandra root, alismatis rhizome, white mustard seed, peach kernel, etc. Its advantage is high curative effect.

The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Fomula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.

A novel, new, and highly effective agent for promoting fat degradation that contains astaxanthin and/or an ester thereof as active ingredient is provided. The agent for promoting fat degradation of the present invention has an effect of reducing fat by lipolysis of fat in either a subject who is in a condition in which fat has already accumulated or a subject who is in a condition in which fat has not yet been accumulated. Accordingly, the agent for promoting fat degradation of the present invention can restore hypertrophied adipocytes to a normal size.

The invention relates to a green papaya chewing tablet made from natural plant fruit papaya, which mainly contains the materials of green papaya powder, sweetener and adhesives; the preparation method comprises following steps: making green papaya powder first; mixing the green papaya powder with other materials; making the mixture into particle materials; drying the particle materials with low temperature; squashing the particle materials into tablets; finally packing the tablets to obtain the product. The green papaya chewing tablet has the advantages of strengthening spleen and stomach, helping digestion, relieving constipation, detoxicating and deswelling, improving lactation, preserving continence, preventing tooth decay, anti-tumor, reducing weight, enlarging breast, and being suitable for general population, more particularly for the female friends.

Provided herein are pharmaceutical and cosmetic formulations and methods for regional adiposity reduction and treatment of body contour defects such as abdominal bulging; comprising an injectable formulation, said formulation comprising: an active ingredient that consists essentially of an adipose tissue-reducing amount of one or more lipophilic long-acting selective beta-2 adrenergic receptor agonists, or salts, solvates, or polymorphs thereof; and one or more subcutaneously acceptable inactive ingredients.